Pasar al contenido principal

DESCIFRANDO LAS INTERACCIONES MICOBACTERIA-HUESPED ESENCIALES PARA SU USO EN EL TRATAMIENTO DEL CANCER

RTI2018-098777-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Genomic analysis of Mycobacterium brumae sustains its nonpathogenic and immunogenic phenotype

  • Renau-Mínguez, Chantal
  • Herrero-Abadía, Paula
  • Ruiz-Rodríguez, Paula
  • Sentandreu, Vicente
  • Torrents, Eduard
  • Chiner-Oms, Álvaro
  • Torres-Puente, Manuela
  • Comas, Iñaki
  • Julián, Esther
  • Coscollá, Mireia
Mycobacterium brumae is a rapid-growing, non-pathogenic Mycobacterium species, originally isolated from environmental and human samples in Barcelona, Spain. Mycobacterium brumae is not pathogenic and it's in vitro phenotype and immunogenic properties have been well characterized. However, the knowledge of its underlying genetic composition is still incomplete. In this study, we first describe the 4 Mb genome of the M. brumae type strain ATCC 51384T assembling PacBio reads, and second, we assess the low intraspecies variability by comparing the type strain with Illumina reads from three additional strains. Mycobacterium brumae genome is composed of a circular chromosome with a high GC content of 69.2% and containing 3,791 CDSs, 97 pseudogenes, one prophage and no CRISPR loci. Mycobacterium brumae has shown no pathogenic potential in in vivo experiments, and our genomic analysis confirms its phylogenetic position with other non-pathogenic and rapid growing mycobacteria. Accordingly, we determined the absence of virulence-related genes, such as ESX-1 locus and most PE/PPE genes, among others. Although the immunogenic potential of M. brumae was proved to be as high as Mycobacterium bovis BCG, the only mycobacteria licensed to treat cancer, the genomic content of M. tuberculosis T cell and B cell antigens in M. brumae genome is considerably lower than those antigens present in M. bovis BCG genome. Overall, this work provides relevant genomic data on one of the species of the mycobacterial genus with high therapeutic potential., This research was funded by the Spanish Ministry of Science, Innovation, and Universities (MICIN) and co-funded by the FEDER Funds (RTI2018-098777-B-I00, RTI2018-094399-A-I00, PID2021-125801OB-I00, PID2021-122331OB-I00, and PID2021-123443OB-I00), the AGAUR-Generalitat of Catalunya (2017SGR229 and 2017SGR-1079), Ramón y Cajal fellowship (RYC-2015-18213 MICIN), FPI fellowship (PRE-2019-088141 MICIN), Generalitat Valenciana (SEJI/2019/011), MycoNET (RED2018-102677-T), and the European Commission—NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Program (PTI+ Salud Global)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mycolicibacterium brumae is a safe and non-toxic immunomodulatory agent for cancer treatment

  • Bach Griera, Marc|||0000-0001-9845-7225
  • Campo Pérez, Víctor|||0000-0003-3161-9984
  • Barbosa Perez, Sandra
  • Traserra Call, Sara
  • Guallar Garrido, Sandra|||0000-0002-9666-5757
  • Moya Andérico, Laura|||0000-0001-8471-9853
  • Herrero Abadía, Paula|||0000-0001-9747-1818
  • Luquin Fernandez, Marina de la Milagrosa|||0000-0002-6015-3282
  • Rabanal Prados, Rosa Ma|||0000-0002-9521-791X
  • Torrents, Eduard|||0000-0002-3010-1609
  • Julián, Esther|||0000-0002-6558-3978
Intravesical Mycobacterium bovis Bacillus Calmette-Guérin (BCG) immunotherapy remains the gold-standard treatment for non-muscle-invasive bladder cancer patients, even though half of the patients develop adverse events to this therapy. On exploring BCG-alternative therapies, Mycolicibacterium brumae, a nontuberculous mycobacterium, has shown outstanding anti-tumor and immunomodulatory capabilities. As no infections due to M. brumae in humans, animals, or plants have been described, the safety and/or toxicity of this mycobacterium have not been previously addressed. In the present study, an analysis was made of M. brumae - and BCG-intravenously-infected severe combined immunodeficient (SCID) mice, M. brumae -intravesically-treated BALB/c mice, and intrahemacoelic-infected- Galleria mellonella larvae. Organs from infected mice and the hemolymph from larvae were processed to count bacterial burden. Blood samples from mice were also taken, and a wide range of hematological and biochemical parameters were analyzed. Finally, histopathological alterations in mouse tissues were evaluated. Our results demonstrate the safety and non-toxic profile of M. brumae. Differences were observed in the biochemical, hematological and histopathological analysis between M. brumae and BCG-infected mice, as well as survival curves rates and colony forming units (CFU) counts in both animal models. M. brumae constitutes a safe therapeutic biological agent, overcoming the safety and toxicity disadvantages presented by BCG in both mice and G. mellonella animal models.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

BCG Substrains Change Their Outermost Surface as a Function of Growth Media

  • Guallar Garrido, Sandra|||0000-0002-9666-5757
  • Almiñana-Rapún, Farners
  • Campo Pérez, Víctor|||0000-0003-3161-9984
  • Torrents, Eduard|||0000-0002-3010-1609
  • Luquin Fernandez, Marina de la Milagrosa|||0000-0002-6015-3282
  • Julián, Esther|||0000-0002-6558-3978
Mycobacterium bovis bacillus Calmette-Guérin (BCG) efficacy as an immunotherapy tool can be influenced by the genetic background or immune status of the treated population and by the BCG substrain used. BCG comprises several substrains with genetic differences that elicit diverse phenotypic characteristics. Moreover, modifications of phenotypic characteristics can be influenced by culture conditions. However, several culture media formulations are used worldwide to produce BCG. To elucidate the influence of growth conditions on BCG characteristics, five different substrains were grown on two culture media, and the lipidic profile and physico-chemical properties were evaluated. Our results show that each BCG substrain displays a variety of lipidic profiles on the outermost surface depending on the growth conditions. These modifications lead to a breadth of hydrophobicity patterns and a different ability to reduce neutral red dye within the same BCG substrain, suggesting the influence of BCG growth conditions on the interaction between BCG cells and host cells.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Bacillus Calmette-Guérin (BCG) Therapy for Bladder Cancer, An Update

  • Guallar Garrido, Sandra|||0000-0002-9666-5757
  • Julián, Esther|||0000-0002-6558-3978
Physicians treating patients affected by nonmuscle-invasive bladder cancer (NMIBC) have been in shock during the last six years since manufacturing restrictions on the production of the first-option medicine, Mycobacterium bovis Bacillus Calmette-Guérin (BCG), have resulted in worldwide shortages. This shortage of BCG has led to a rethinking of the established treatment guidelines for the rationing of the administration of BCG. Some possible schedule modifications consist of a decrease in the length of maintenance treatment, a reduction in the dose of BCG in intravesical instillations or the use of different BCG substrains. All these strategies have been considered valuable in times of BCG shortage. In addition, the lack of availability of BCG has also led to the general recognition of the need to find new treatment options for these patients so that they are not dependent on a single treatment. Few alternatives are committed to definitively replacing BCG intravesical instillations, but several options are being evaluated to improve its efficacy or to combine it with other chemotherapeutic or immunotherapeutic options that can also improve its effect. In this article, we review the current state of the treatment with BCG in terms of all of the aforementioned aspects.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Each Mycobacterium Requires a Specific Culture Medium Composition for Triggering an Optimized Immunomodulatory and Antitumoral Effect

  • Guallar Garrido, Sandra|||0000-0002-9666-5757
  • Campo Pérez, Víctor|||0000-0003-3161-9984
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Luquin Fernandez, Marina de la Milagrosa|||0000-0002-6015-3282
  • Julián, Esther|||0000-0002-6558-3978
Mycobacterium bovis bacillus Calmette-Guérin (BCG) remains the first treatment option for non-muscle-invasive bladder cancer (BC) patients. In research laboratories, M. bovis BCG is mainly grown in commercially available media supplemented with animal-derived agents that favor its growth, while biomass production for patient treatment is performed in Sauton medium which lacks animal-derived components. However, there is not a standardized formulation of Sauton medium, which could affect mycobacterial characteristics. Here, the impact of culture composition on the immunomodulatory and antitumor capacity of M. bovis BCG and Mycolicibacterium brumae, recently described as efficacious for BC treatment, has been addressed. Both mycobacteria grown in Middlebrook and different Sauton formulations, differing in the source of nitrogen and amount of carbon source, were studied. Our results indicate the relevance of culture medium composition on the antitumor effect triggered by mycobacteria, indicating that the most productive culture medium is not necessarily the formulation that provides the most favorable immunomodulatory profile and the highest capacity to inhibit BC cell growth. Strikingly, each mycobacterial species requires a specific culture medium composition to provide the best profile as an immunotherapeutic agent for BC treatment. Our results highlight the relevance of meticulousness in mycobacteria production, providing insight into the application of these bacteria in BC research.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mycobacteria-Based Vaccines as Immunotherapy for Non-urological Cancers

  • Noguera-Ortega, Estela|||0000-0001-6507-0673
  • Guallar Garrido, Sandra|||0000-0002-9666-5757
  • Julián, Esther|||0000-0002-6558-3978
The arsenal against different types of cancers has increased impressively in the last decade. The detailed knowledge of the tumor microenvironment enables it to be manipulated in order to help the immune system fight against tumor cells by using specific checkpoint inhibitors, cell-based treatments, targeted antibodies, and immune stimulants. In fact, it is widely known that the first immunotherapeutic tools as immune stimulants for cancer treatment were bacteria and still are; specifically, the use of Mycobacterium bovis bacillus Calmette-Guérin (BCG) continues to be the treatment of choice for preventing cancer recurrence and progression in non-invasive bladder cancer. BCG and also other mycobacteria or their components are currently under study for the immunotherapeutic treatment of different malignancies. This review focuses on the preclinical and clinical assays using mycobacteria to treat non-urological cancers, providing a wide knowledge of the beneficial applications of these microorganisms to manipulate the tumor microenvironment aiming at tumor clearance.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mycobacterial surface characters remodeled by growth conditions drive different tumor-infiltrating cells and systemic IFN-γ/IL-17 release in bladder cancer treatment

  • Guallar Garrido, Sandra|||0000-0002-9666-5757
  • Campo Pérez, Víctor|||0000-0003-3161-9984
  • Pérez-Trujillo, Míriam|||0000-0002-6919-7417
  • Cabrera Navarro, Cecilia|||0000-0002-9941-6828
  • Senserrich, Jordi|||0000-0002-8021-1718
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Rabanal Prados, Rosa Ma|||0000-0002-9521-791X
  • Gomez, Elisabet|||0000-0002-9779-5940
  • Noguera-Ortega, Estela|||0000-0001-6507-0673
  • Luquin Fernandez, Marina de la Milagrosa|||0000-0002-6015-3282
  • Julián, Esther|||0000-0002-6558-3978
The mechanism of action of intravesical Mycobacterium bovis BCG immunotherapy treatment for bladder cancer is not completely known, leading to misinterpretation of BCG-unresponsive patients, who have scarce further therapeutic options. BCG is grown under diverse culture conditions worldwide, which can impact the antitumor effect of BCG strains and could be a key parameter of treatment success. Here, BCG and the nonpathogenic Mycobacterium brumae were grown in four culture media currently used by research laboratories and BCG manufacturers: Sauton-A60, -G15 and -G60 and Middlebrook 7H10, and used as therapies in the orthotopic murine BC model. Our data reveal that each mycobacterium requires specific culture conditions to induce an effective antitumor response. since higher survival rates of tumor-bearing mice were achieved using M. brumae -A60 and BCG-G15 than the rest of the treatments. M. brumae -A60 was the most efficacious among all tested treatments in terms of mouse survival, cytotoxic activity of splenocytes against tumor cells, higher systemic production of IL-17 and IFN-ɣ, and bladder infiltration of selected immune cells such as ILCs and CD4. BCG-G15 triggered an antitumor activity based on a massive infiltration of immune cells, mainly CD3 + (CD4 + and CD8 +) T cells, together with high systemic IFN-ɣ release. Finally, a reduced variety of lipids was strikingly observed in the outermost layer of M. brumae -A60 and BCG-G15 compared to the rest of the cultures, suggesting an influence on the antitumor immune response triggered. These findings contribute to understand how mycobacteria create an adequate niche to help the host subvert immunosuppressive tumor actions.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The high plasticity of nonpathogenic Mycobacterium brumae induces rapid changes in its lipid profile during pellicle maturation, The potential of this bacterium as a versatile cell factory for lipid compounds of therapeutic interest

  • Campo Pérez, Víctor|||0000-0003-3161-9984
  • Guallar Garrido, Sandra|||0000-0002-9666-5757
  • Luquin Fernandez, Marina de la Milagrosa|||0000-0002-6015-3282
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Julián, Esther|||0000-0002-6558-3978
The immunomodulatory potential of mycobacteria to be used for therapeutic purposes varies by species and culture conditions and is closely related to mycobacterial lipid composition. Although the lipids present in the mycobacterial cell wall are relevant, lipids are mainly stored in intracellular lipid inclusions (ILIs), which have emerged as a crucial structure in understanding mycobacteria-host interaction. Little is known about ILI ultrastructure, production, and composition in nonpathogenic species. In this study, we compared the lipid profiles of the nonpathogenic immunomodulatory agent Mycobacterium brumae during pellicle maturation under different culture conditions with qualitative and quantitative approaches by using high-resolution imaging and biochemical and composition analyses to understand ILI dynamics. The results showed wax esters, mainly in early stages of development, and acylglycerols in mature ILI composition, revealing changes in dynamics, amount, and morphometry, depending on pellicle maturation and the culture media used. Low-glycerol cultures induced ILIs with lower molecular weights which were smaller in size in comparison with the ILIs produced in glycerol-enriched media. The data also indicate the simple metabolic plasticity of lipid synthesis in M. brumae, as well as its high versatility in generating different lipid profiles. These findings provide an interesting way to enhance the production of key lipid structures via the simple modulation of cell culture conditions.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Remodeling the bladder tumor immune microenvironment by mycobacterial species with changes in their cell envelope composition

  • Senserrich, Jordi|||0000-0002-8021-1718
  • Guallar Garrido, Sandra|||0000-0002-9666-5757
  • Gomez, Elisabet|||0000-0002-9779-5940
  • Urrea, Víctor|||0000-0002-2577-856X
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Julián, Esther|||0000-0002-6558-3978
  • Cabrera Navarro, Cecilia|||0000-0002-9941-6828
Intravesical BCG instillation after bladder tumor resection is the standard treatment for non-muscle invasive bladder cancer; however, it is not always effective and frequently has undesirable side effects. Therefore, new strategies that improve the clinical management of patients are urgently needed. This study aimed to comprehensively evaluate the bladder tumor immune microenvironment profile after intravesical treatment with a panel of mycobacteria with variation in their cell envelope composition and its impact on survival using an orthotopic murine model to identify more effective and safer therapeutic strategies. tumor-bearing mice were intravesically treated with a panel of BCG and M. brumae cultured under different conditions. Untreated tumor-bearing mice and healthy mice were also included as controls. After mycobacterial treatments, the infiltrating immune cell populations in the bladder were analysed by flow cytometry. We provide evidence that mycobacterial treatment triggered a strong immune infiltration into the bladder, with BCG inducing higher global absolute infiltration than M. brumae. The induced global immune microenvironment was strikingly different between the two mycobacterial species, affecting both innate and adaptive immunity. Compared with M. brumae, BCG treated mice exhibited a more robust infiltration of CD4 + and CD8 + T-cells skewed toward an effector memory phenotype, with higher frequencies of NKT cells, neutrophils/gMDSCs and monocytes, especially the inflammatory subset, and higher CD4 + T/CD4 + T and CD8 + T/CD4 + T ratios. Conversely, M. brumae treatment triggered higher proportions of total activated immune cells and activated CD4 + and CD8 + T cells and lower ratios of CD4 + T cells/CD4 + T, CD8 + T cells/CD4 + T and inflammatory/reparative monocytes. Notably, the mycobacterial cell envelope composition in M. brumae had a strong impact on the immune microenvironment, shaping the B and myeloid cell compartment and T-cell maturation profile and thus improving survival. Overall, we demonstrate that the bladder immune microenvironment induced by mycobacterial treatment is species specific and shaped by mycobacterial cell envelope composition. Therefore, the global bladder immune microenvironment can be remodelled, improving the quality of infiltrating immune cells, the balance between inflammatory and regulatory/suppressive responses and increasing survival.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genomic analysis of Mycobacterium brumae sustains its nonpathogenic and immunogenic phenotype

  • Renau-Mínguez, Chantal
  • Herrero Abadía, Paula|||0000-0001-9747-1818
  • Ruiz-Rodriguez, Paula
  • Sentandreu, Vicente
  • Torrents, Eduard|||0000-0002-3010-1609
  • Chiner-Oms, Álvaro|||0000-0002-0463-0101
  • Torres-Puente, Manuela|||0000-0002-8352-180X
  • Comas, I.|||0000-0001-5504-9408
  • Julián, Esther|||0000-0002-6558-3978
  • Coscolla, Mireia
Mycobacterium brumae is a rapid-growing, non-pathogenic Mycobacterium species, originally isolated from environmental and human samples in Barcelona, Spain. Mycobacterium brumae is not pathogenic and it's in vitro phenotype and immunogenic properties have been well characterized. However, the knowledge of its underlying genetic composition is still incomplete. In this study, we first describe the 4 Mb genome of the M. brumae type strain ATCC 51384 T assembling PacBio reads, and second, we assess the low intraspecies variability by comparing the type strain with Illumina reads from three additional strains. Mycobacterium brumae genome is composed of a circular chromosome with a high GC content of 69.2% and containing 3,791 CDSs, 97 pseudogenes, one prophage and no CRISPR loci. Mycobacterium brumae has shown no pathogenic potential in in vivo experiments, and our genomic analysis confirms its phylogenetic position with other non-pathogenic and rapid growing mycobacteria. Accordingly, we determined the absence of virulence-related genes, such as ESX-1 locus and most PE/PPE genes, among others. Although the immunogenic potential of M. brumae was proved to be as high as Mycobacterium bovis BCG, the only mycobacteria licensed to treat cancer, the genomic content of M. tuberculosis T cell and B cell antigens in M. brumae genome is considerably lower than those antigens present in M. bovis BCG genome. Overall, this work provides relevant genomic data on one of the species of the mycobacterial genus with high therapeutic potential.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A high-throughput microtiter plate screening assay to quantify and differentiate species in dual-species biofilms

  • Campo Pérez, Víctor|||0000-0003-3161-9984
  • Alcàcer-Almansa, Júlia|||0000-0002-8688-3128
  • Julián, Esther|||0000-0002-6558-3978
  • Torrents, Eduard|||0000-0002-3010-1609
Pathogenic bacteria form biofilms during infection, and polymicrobial biofilms are the most frequent manifestation. Biofilm attachment, maturation, and/or antibiotic sensitivity are mainly evaluated with microtiter plate assays, in which bacteria are stained to enable the quantification of the biomass by optical absorbance or fluorescence emission. However, using these methods to distinguish different species in dual-species or polymicrobial biofilms is currently impossible. Colony-forming unit counts from homogenized dual-species biofilms on selective agar medium allow species differentiation but are time-consuming for a high-throughput screening. Thus, reliable, feasible, and fast methods are urgently needed to study the behavior of polymicrobial and dual-species communities. This study shows that Pseudomonas aeruginosa and Burkholderia cenocepacia strains expressing specific fluorescent or bioluminescent proteins permit the more efficient study of dual-species biofilms compared to other methods that rely on measuring the total biomass. Combining fluorescence and bioluminescence measurements allows an independent analysis of the different microbial species within the biofilm, indicating the degree of presence of each one over time during a dual-species biofilm growth. The quantitative strategies developed in this work are reproducible and recommended for dual-species biofilm studies with high-throughput microtiter plate approaches using strains that can constitutively express fluorescent or bioluminescent proteins.